A 5-month, randomized, placebo-controlled trial of galantamine in AD

Neurology

Volumn 54, Issue 12, 2000, Pages 2269-2276

  Tariot, Pierre N ^e   Solomon, P R ^a   Morris, J C ^b   Kershaw, P ^c   Lilienfeld, S ^d   Ding, C ^c  

^a Southwestern Vermont Medical Center   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e Monroe Community Hospital   (United States)

Author keywords

Acetylcholinesterase inhibition; AD; Allosteric modulation; Dose escalation; Efficacy; Galantamine; Nicotinic receptors; Randomized controlled trial; Tolerability

Indexed keywords

GALANTAMINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034720864     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.12.2269     Document Type: Article

References (37)

1. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217: 408-414.
2. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
3. Nordberg A, Svensson A-L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998;19:465-480.
4. Schneider LS. New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry 1996;57(suppl 14):30-36.
5. Vasilenko ET, Tonkopii VD. Characteristics of galanthamine as a reversible inhibitor of cholinesterase [in Russian]. Biokhimiia 1974;39:701-703.
6. Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996;277:728-738.
7. Schrattenholz A, Pereira EFR, Roth U, Weber K, Albuquerque EX, Maelicke A. Agonist responses of neuronal acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996;49:1-6.
8. Albuquerque EX, Alkondon M, Pereira EFR, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117-1136.
9. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berlin) 1998;138:217-230.
10. Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986;371:146-151.
11. Nordberg A, Nilsson-Hakansson L, Adem A, et al. The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res 1989;79:353-362.
12. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268.
13. Farlow MR, Evans RM. Pharmacological treatment of cognition in Alzheimer's dementia. Neurology 1998;51(suppl 1): S36-S44.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatr 1984;141:1356-1364.
17. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22-S32.
18. Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee Meeting; July 7, 1989. Rockville, MD: Dept. of Health and Human Services, Public Heath Service, Food and Drug Administration, 1989: 227.
19. Galasko D, Bennett D, Sano M, et al. An inventory to assess the activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alz Dis Assoc Disord 1997;11(suppl 2):S33-S39.
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory. Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
21. Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Inst Intern Stat 1960;37:351-361.
22. Koch GG, Gansky SA. Statistical considerations for multiplicity in confirmatory protocols. Drug Information J 1996;30: 523-534.
23. Tariot PN. Treatment of agitation in dementia. J Clin Psychiatry 1999;60(suppl 8):11-20.
24. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115.
25. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
26. The Canadian Study of Health and Aging. Patterns of caring for people with dementia in Canada. Can J Aging 1994;13: 470-487.
27. Teri L, Borson S, Kiyak HA, Yamagashi M. Behavioral disturbance, cognitive dysfunction and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc 1989;37:109-116.
28. Brodaty H, McGilchrist C, Harris L, Peters K. Time until institutionalization and death in patients with dementia. Arch Neurol 1993;50:643-650.
29. Rösler M, Anand R, Cicin-Sain A, et al., on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-638.
30. Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. J Clin Psychiatry 1999;60:318-325.
31. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
32. Kaufer DI, Cummings JL, Christine D. Effects of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
33. Mega M, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer's disease. Arch Neurol 1999;56:1388-1393.
34. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
35. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-883.
36. Newhouse PA, Potter A, Levin ED. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 1997;11:206-228.
37. Moller H-J. Reappraising neurotransmitter-based strategies. Eur Neuropsychopharmacol 1999;9(suppl 2):S53-S59.